Document Detail


NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
MedLine Citation:
PMID:  20428172     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The inflammatory nature of atherosclerosis is well established but the agent(s) that incite inflammation in the artery wall remain largely unknown. Germ-free animals are susceptible to atherosclerosis, suggesting that endogenous substances initiate the inflammation. Mature atherosclerotic lesions contain macroscopic deposits of cholesterol crystals in the necrotic core, but their appearance late in atherogenesis had been thought to disqualify them as primary inflammatory stimuli. However, using a new microscopic technique, we revealed that minute cholesterol crystals are present in early diet-induced atherosclerotic lesions and that their appearance in mice coincides with the first appearance of inflammatory cells. Other crystalline substances can induce inflammation by stimulating the caspase-1-activating NLRP3 (NALP3 or cryopyrin) inflammasome, which results in cleavage and secretion of interleukin (IL)-1 family cytokines. Here we show that cholesterol crystals activate the NLRP3 inflammasome in phagocytes in vitro in a process that involves phagolysosomal damage. Similarly, when injected intraperitoneally, cholesterol crystals induce acute inflammation, which is impaired in mice deficient in components of the NLRP3 inflammasome, cathepsin B, cathepsin L or IL-1 molecules. Moreover, when mice deficient in low-density lipoprotein receptor (LDLR) were bone-marrow transplanted with NLRP3-deficient, ASC (also known as PYCARD)-deficient or IL-1alpha/beta-deficient bone marrow and fed on a high-cholesterol diet, they had markedly decreased early atherosclerosis and inflammasome-dependent IL-18 levels. Minimally modified LDL can lead to cholesterol crystallization concomitant with NLRP3 inflammasome priming and activation in macrophages. Although there is the possibility that oxidized LDL activates the NLRP3 inflammasome in vivo, our results demonstrate that crystalline cholesterol acts as an endogenous danger signal and its deposition in arteries or elsewhere is an early cause rather than a late consequence of inflammation. These findings provide new insights into the pathogenesis of atherosclerosis and indicate new potential molecular targets for the therapy of this disease.
Authors:
Peter Duewell; Hajime Kono; Katey J Rayner; Cherilyn M Sirois; Gregory Vladimer; Franz G Bauernfeind; George S Abela; Luigi Franchi; Gabriel Nuñez; Max Schnurr; Terje Espevik; Egil Lien; Katherine A Fitzgerald; Kenneth L Rock; Kathryn J Moore; Samuel D Wright; Veit Hornung; Eicke Latz
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Nature     Volume:  464     ISSN:  1476-4687     ISO Abbreviation:  Nature     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-29     Completed Date:  2010-06-15     Revised Date:  2011-03-21    
Medline Journal Info:
Nlm Unique ID:  0410462     Medline TA:  Nature     Country:  England    
Other Details:
Languages:  eng     Pagination:  1357-61     Citation Subset:  IM    
Affiliation:
Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Atherosclerosis / chemically induced,  metabolism*,  pathology*
Bone Marrow Transplantation
Carrier Proteins / genetics,  metabolism*
Cathepsin B / metabolism
Cathepsin L / metabolism
Cholesterol / chemistry*,  metabolism*,  pharmacology
Crystallization
Cytoskeletal Proteins / deficiency
Diet, Atherogenic
Female
Humans
Inflammation / chemically induced,  metabolism,  pathology
Interleukin-1 / deficiency
Interleukin-18 / metabolism
Lysosomes / drug effects,  pathology
Mice
Mice, Inbred C57BL
Peritoneal Cavity / pathology
Phagocytes / drug effects,  pathology,  physiology
Receptors, LDL / deficiency
Time Factors
Grant Support
ID/Acronym/Agency:
R01 AI075318-03/AI/NIAID NIH HHS; R01 AI083713-01/AI/NIAID NIH HHS; R01 HL093262-01A1/HL/NHLBI NIH HHS; R01 HL093262-03/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/CIAS1 protein, mouse; 0/Carrier Proteins; 0/Cytoskeletal Proteins; 0/Interleukin-1; 0/Interleukin-18; 0/Pycard protein, mouse; 0/Receptors, LDL; 57-88-5/Cholesterol; EC 3.4.22.1/Cathepsin B; EC 3.4.22.1/Ctsb protein, mouse; EC 3.4.22.15/Cathepsin L; EC 3.4.22.15/Ctsl protein, mouse
Comments/Corrections
Erratum In:
Nature. 2010 Jul 29;466(7306):652

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis.
Next Document:  Congenital pneumonia with sepsis caused by intrauterine infection of Ureaplasma parvum in a term new...